Pancreatic Cancer Detection Consortium

Last updated: April 29, 2025
Sponsor: City of Hope Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pancreatic Cancer

Pancreatitis

Carcinoma

Treatment

PANcreatic cancer Exosome Early detectiON (PANXEON)

Clinical Study ID

NCT06388967
19288/PCDC
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNMclassification, 8th edition)

  • Received standard diagnostic and staging procedures as per local guidelines, and atleast one sample was drawn before receiving any curative-intent treatment.

  • Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at thetime of sampling (Non-disease controls)

Exclusion

Exclusion Criteria:

  • Lack of written informed consent.

Study Design

Total Participants: 2000
Treatment Group(s): 1
Primary Treatment: PANcreatic cancer Exosome Early detectiON (PANXEON)
Phase:
Study Start date:
March 15, 2023
Estimated Completion Date:
November 21, 2025

Study Description

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer. It often goes undetected until it is at an advanced stage, making it challenging to treat. Currently, only a small percentage of patients are diagnosed early enough for effective treatment. While a blood marker exists, called serum carbohydrate antigen 19-9 (CA19-9), it is used primarily to track the disease and it is unreliable for early detection.

To address this problem, the researchers have developed a new method to analyze circulating vesicles (called exosomes), which contain specific genetic material called microRNAs (miRNAs). In a previous study, by analyzing both the miRNAs that circulate freely in serum and the miRNAs that are inside the exosomes, the researchers have already identified a combination of 13 miRNAs that could accurately detect early-stage PDAC.

In this study, the researchers will test this method in a larger international cohort study. This study aims to confirm the effectiveness of this approach in accurately identifying PDAC at its earliest stages.

Connect with a study center

  • Nagoya University

    Nagoya,
    Japan

    Active - Recruiting

  • Asan Medical Center

    Seoul,
    Korea, Republic of

    Active - Recruiting

  • Translational Genomics Research Institute

    Phoenix, Arizona 85004
    United States

    Active - Recruiting

  • Honorhealth

    Scottsdale, Arizona 85258
    United States

    Active - Recruiting

  • City of Hope Medical Center

    Monrovia, California 91016
    United States

    Active - Recruiting

  • Hoag Center

    Newport Beach, California 92663
    United States

    Active - Recruiting

  • OSF HealthCare

    Peoria, Illinois 61637
    United States

    Active - Recruiting

  • Ochsner Medical Center

    Jefferson, Louisiana 70121
    United States

    Active - Recruiting

  • Atlantic Health System

    Morristown, New Jersey 07960
    United States

    Active - Recruiting

  • Piedmont Medical Center

    Rock Hill, South Carolina 29732
    United States

    Active - Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin 53226
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.